Clinical Trial: A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07623642) titled 'A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.' on May 29.

Brief Summary: This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors who are refractory to, intolerant of, or ineligible for standard of care.

Study Start Date: June 02

Study Type: INTERVENTIONAL

Condition: Uterine Cervical Neoplasms Triple Negative Breast Neoplasms Prostatic Neoplasms Squam...